利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3707 条记录 (耗时 0.052 秒)

    CAVITY-SEPARATED MULTI-NANOPORE DEVICE AND METHOD PROVIDING PROTEIN SEQUENCING
    56.
    发明公开
    CAVITY-SEPARATED MULTI-NANOPORE DEVICE AND METHOD PROVIDING PROTEIN SEQUENCING 审中-公开

    公开(公告)号：US20230356218A1

    公开(公告)日：2023-11-09

    申请号：US18121311

    申请日：2023-03-14

    申请人： The Trustees of Columbia University in the City of New York

    发明人： Jakob Buchheim ,  Kenneth Shepard

    IPC分类号： B01L3/00

    CPC分类号： B01L3/502715 ,  B01L2300/0645 ,  B01L2300/0861

    摘要： An exemplary system and method can be provided, e.g., for detecting a molecular size and charge. The exemplary system can comprise a cavity, nanopores separated by the cavity, and electrolyte reservoirs. Each of the reservoirs can be provided on a side of a respective nanopore, and within the cavity. A plurality of such systems can be integrated in a surface of a complementary metal-oxide-semiconductor (CMOS) integrated circuit, which can comprise transimpedance amplifiers configured to measure a conductance through the nanopores. Further an exemplary device can be provided for protein sequencing, and can comprise a first compartment with a first electrode, a second compartment with a second electrode, and a channel between the first and second compartments. Each of the compartments can be fluidly coupled to the channel using a nanopore. A detector can also be provided which is configured to record at least one parameter in the channel by applying a voltage bias across the first and second electrodes so that charged molecules pass through the nanopore fluidly coupled to the first and second compartments.

    COMPOSITIONS AND METHODS FOR ENHANCING NUCLEIC ACID THERAPEUTICS
    59.
    发明公开
    COMPOSITIONS AND METHODS FOR ENHANCING NUCLEIC ACID THERAPEUTICS 审中-公开

    公开(公告)号：US20230303645A1

    公开(公告)日：2023-09-28

    申请号：US18312859

    申请日：2023-05-05

    申请人： The Trustees of Columbia University in the City of New York

    发明人： Fatemeh Momen HERAVI ,  Akiva MINTZ

    IPC分类号： C07K14/47 ,  C12N15/113 ,  C12N15/86

    CPC分类号： C07K14/4703 ,  C12N15/113 ,  C12N15/86

    摘要： The compositions for enhancing nucleic acid therapeutics are used in the treatment or prevention of diseases or conditions. The compositions improve the use of nucleic acid therapeutics with the use of enhancing or stabilizing elements, such as RNA-induced silencing complex (RISC) proteins. The compositions include at least one nucleic acid therapeutic or a polynucleotide encoding at least one nucleic acid therapeutic; at least one enhancing or stabilizing element, mutant, variant or modified form thereof, or a polynucleotide encoding at least one enhancing or stabilizing element, mutant, variant or Modified form thereof; and a delivery vehicle, where the delivery vehicle may be exosomes, microvesicles, apoptotic bodies, oncosomes, microparticles, extracellular vesicles, liposomes, nanoparticles, plasmids or vectors. The exosomes or extracellular vesicles may be engineered to be substantially devoid of endogenous nucleic acids by downregulating or inhibiting at least one protein involved in sorting or loading nucleic acids into exosomes or extracellular vesicles.

    METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS
    60.
    发明公开
    METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS 审中-公开

    公开(公告)号：US20230302013A1

    公开(公告)日：2023-09-28

    申请号：US18166875

    申请日：2023-02-09

    申请人： The Trustees of Columbia University in the City of New York

    发明人： Andrew R. MARKS

    IPC分类号： A61K31/554 ,  A61K31/675

    CPC分类号： A61K31/554 ,  A61K31/675

    摘要： A method for treating cognitive dysfunction by administering a therapeutically effective amount of a calcium channel stabilizer to a subject in need thereof. The preferred calcium channel stabilizers include a 1,4-benzothiazepine moiety, including those of the general structural formula:




    The method is useful with various types of respiratory viruses, including for coronaviruses, COVID, SARS and MERS. The method of treatment increases RyR2-Castabin2 binding in cardiac muscle of the subject while also decreasing open probability (Po) of RyR2 protein in the subject. All of these effects act to at least partially offset cognitive dysfunctions such as a deficit in attention, executive functioning, language, processing speed, memory, and combinations thereof.